Seqens Seqens

X
[{"orgOrder":0,"company":"Tracer","sponsor":"Akston Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tracer to Support Akston Biosciences\u2019 Phase 1 Clinical Study of AKS-452, an Innovative Anti-Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"NETHERLANDS","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"}]

Find Clinical Drug Pipeline Developments & Deals by Tracer

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            TRACER will will provide regulatory services, oversight of local manufacturing contractors as well as Phase 1 Study preparation and clinical site management for Akston Biosciences' Phase 1 clinical testing in of its lead COVID-19 vaccine candidate, AKS-452.

            Lead Product(s): AKS-452

            Therapeutic Area: Infections and Infectious Diseases Product Name: AKS-452

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: Akston Biosciences

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration September 01, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY